Abstract
Glutamate carboxypeptidase II (GCPII) and its splice variants, paralogs and human homologs represent a family of proteins with diverse tissue distribution, cellular localization and largely unknown function which have been explored only recently. While GCPII itself has been thoroughly studied from different perspectives, as clearly documented in this series of reviews, very little is known about other members of its family, even though they might be biologically relevant. Differential expression of individual GCPII splice variants is associated with tumor progression and prognosis of prostate cancer. The best studied GCPII homolog, GCPIII or NAALADase II, may be a valid pharmaceutical target for itself since it may compensate for a lack of normal GCPII enzymatic activity. Detailed molecular characterization of this family of proteins is thus very important not only with respect to the potential therapeutic use of GCPII inhibitors, but also for better understanding of the biological role of GCPII within as well as outside the nervous system.
Keywords: PSMA, GCPIII, NAALADase L, PSMAL, Splice variants, Homologs, Glutamate carboxypeptidase II (GCPII), biological role, cancer metastasis
Current Medicinal Chemistry
Title: GCPII Variants, Paralogs and Orthologs
Volume: 19 Issue: 9
Author(s): K. Hlouchova, V. Navratil, J. Tykvart, P. Sacha and J. Konvalinka
Affiliation:
Keywords: PSMA, GCPIII, NAALADase L, PSMAL, Splice variants, Homologs, Glutamate carboxypeptidase II (GCPII), biological role, cancer metastasis
Abstract: Glutamate carboxypeptidase II (GCPII) and its splice variants, paralogs and human homologs represent a family of proteins with diverse tissue distribution, cellular localization and largely unknown function which have been explored only recently. While GCPII itself has been thoroughly studied from different perspectives, as clearly documented in this series of reviews, very little is known about other members of its family, even though they might be biologically relevant. Differential expression of individual GCPII splice variants is associated with tumor progression and prognosis of prostate cancer. The best studied GCPII homolog, GCPIII or NAALADase II, may be a valid pharmaceutical target for itself since it may compensate for a lack of normal GCPII enzymatic activity. Detailed molecular characterization of this family of proteins is thus very important not only with respect to the potential therapeutic use of GCPII inhibitors, but also for better understanding of the biological role of GCPII within as well as outside the nervous system.
Export Options
About this article
Cite this article as:
Hlouchova K., Navratil V., Tykvart J., Sacha P. and Konvalinka J., GCPII Variants, Paralogs and Orthologs, Current Medicinal Chemistry 2012; 19 (9) . https://dx.doi.org/10.2174/092986712799462676
DOI https://dx.doi.org/10.2174/092986712799462676 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cytokine-Induced Depression: Current Status and Novel Targets for Depression Therapy
CNS & Neurological Disorders - Drug Targets An Advanced Computational Evaluation for the Most Biologically Active Enantiomers of Chiral Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Hair Growth: Focus on Herbal Therapeutic Agent
Current Drug Discovery Technologies In Vitro and In Vivo Antimetastatic Effects of ZSTK474 on Prostate Cancer DU145 Cells
Current Cancer Drug Targets MicroRNAs: Regulators of TLR2-Mediated Probiotic Immune Responses
MicroRNA Recent Patents on Common Modifications Made to Traditional Micellar- Based Chemotherapeutics Designed to Improve Drug Delivery
Recent Patents on Nanomedicine Disposition of Flavonoids Impacts their Efficacy and Safety
Current Drug Metabolism Electroporation in DNA Vaccination Protocols Against Cancer
Current Drug Metabolism Non-Analgesic Effects of Opioids: Opioids and the Endocrine System
Current Pharmaceutical Design Small Molecules ATP-Competitive Inhibitors of FLT3: A Chemical Overview
Current Medicinal Chemistry Therapeutic Potential of High Mobility Group Box-1 in Ischemic Injury and Tissue Regeneration
Current Vascular Pharmacology Targeting Aurora Kinases: A Novel Approach to Curb the Growth & Chemoresistance of Androgen Refractory Prostate Cancer
Current Cancer Drug Targets Characterization of Molecular and Functional Alterations of Tumor Endothelial Cells to Design Anti-Angiogenic Strategies
Current Vascular Pharmacology Preparation of Quantum Dot Bioconjugates and their Applications in Bio-Imaging
Current Pharmaceutical Biotechnology The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer
Current Pharmaceutical Design An Unbiased Predictive Model to Detect DNA Methylation Propensity of CpG Islands in the Human Genome
Current Bioinformatics A Critical View on Antimalarial Endoperoxide QSAR Studies
Mini-Reviews in Medicinal Chemistry Stem Cells and the Side Population Theory: A Critical Review
Current Tissue Engineering (Discontinued) Plastid Molecular Pharming II. Production of Biopharmaceuticals by Plastid Transformation
Mini-Reviews in Medicinal Chemistry Bowman-Birk Inhibitors from Legumes and Human Gastrointestinal Health: Current Status and Perspectives
Current Protein & Peptide Science